Form 4: Apellis Pharmaceuticals CEO Cedric Francois Executes Stock Options and Sells Shares Under 10b5-1 Trading Plan

Apellis Pharmaceuticals CEO Cedric Francois exercised stock options and sold shares of common stock on March 1, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Cedric Francois, CEO of Apellis Pharmaceuticals, executed stock options and sold shares of common stock on March 1, 2024.
• The transactions were made pursuant to a pre-arranged 10b5-1 trading plan dated November 30, 2023.
• Francois exercised options to acquire 50,000 shares at $3.76 and 200,000 shares at $4.31.
• He then sold 28,868 shares at an average price of $62.213, 41,704 shares at an average price of $62.9631, 62,503 shares at an average price of $64.2573, 116,512 shares at an average price of $64.9163, and 413 shares at an average price of $65.68.
• Following these transactions, Francois directly owns 313,662 shares of common stock.
• Francois also indirectly owns shares through various trusts, including The Cedric Francois Irrevocable Trust of 2023 2 (532,946 shares), The Cedric Francois Irrevocable Trust of 2023 (654,211 shares), The Francois Grossi Trust (300,000 shares), and The Francois-DuBois Educational Trust (234,411 shares).
• Francois disclaims beneficial ownership of the shares held by these trusts except to the extent of his pecuniary interest therein.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transactions were part of a pre-planned trading strategy and do not necessarily reflect a change in the CEO's outlook on the company.

Industry Context

Insider transactions are common, and the use of 10b5-1 trading plans allows corporate insiders to sell shares over a predetermined period, mitigating concerns about trading on non-public information. The market will likely interpret these sales in the context of the company's overall performance and future prospects.

Comparison to Industry Standards

• It's common for CEOs of publicly traded companies, including those in the pharmaceutical sector like Regeneron, Vertex, and BioMarin, to have pre-arranged trading plans to manage their stock holdings.
• The volume and frequency of these transactions are generally compared to the executive's overall compensation package and the company's stock performance.
• The market often scrutinizes these transactions to gauge executive confidence in the company's future prospects, comparing them to similar transactions by executives at comparable companies.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, depending on how the market interprets the insider selling.
• The impact on employees, customers, suppliers, and creditors is likely to be negligible.

Key Dates